Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.40
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.80 (8.889%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.40
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

Mon, 07th Jun 2021 10:38

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

NetScientific PLC, up 36% at 102.00 pence, 12-month range 102.00p-4.62p. Subsidiary ProAxsis Ltd enters exclusive licensing agreement with FTSE 100-listed AstraZeneca PLC. ProAxsis will take responsibility for completing the validation and global commercialisation of a SARS-CoV-2 serology enzyme-linked immunosorbent assay developed by internal research team at AstraZeneca. "In return for providing access to the required intellectual property and technical know-how, AstraZeneca will receive an undisclosed royalty fee on future global net sales of the assay," it says.

----------

EPE Special Opportunities Ltd, up 8.4% at 375.00p, 12-month range 380p-155p. Hits this 12-month high earlier on Monday. The investment company says that its EPIC Investments LLP sells 4.5 million shares in Luceco PLC, worth GBP15.0 million. Shares sold represent 11% of firm's interest in Luceco, and it plans to use the proceeds for new investments. Luceco shares trading up 3.0% at 358.5p.

----------

Directa Plus PLC, up 8.3% at 130.00p, 12-month range 59p-160p. The producer of graphene nanoplatelets-based products says its customer NexTech Batteries Inc has formed a wholly owned Italian subsidiary, NexTech Italia SpA, with initial objective to evaluate feasibility of producing cathode active materials in Italy, using Directa Plus's G+ graphene nanoplatelets, for the manufacture of Lithium-Sulphur batteries throughout Europe. "This is a key building block in laying the foundation for strategic growth. We will work together with existing partners of Directa Plus, located in several countries across the European Union, to support the development of Lithium-Sulphur batteries in Europe," says Directa Plus Founder & Chief Executive Giulio Cesareo.

----------

Scancell Holdings PLC, up 8.1% at 21.35p, 12-month range 5.01p-29p. Says Vulpes Life Sciences Fund, which is closely associated with Non-Executive Martin Diggle, buys 400,000 shares at 19.25p each, worth GBP77,000. This takes Vulpes's total interest to 117.0 million shares, representing just over 14% stake in Scancell.

----------

AIM - LOSERS

----------

Steppe Cement Ltd, down 13% at 45p, 12-month range 21p-55.25p. The Kazakhstan-focused construction materials firm says revenue in 2020 slips 6% to USD74.8 million from USD79.9 million in 2019, though pretax profit rises 5% to USD13.1 million from USD12.5 million. Profit improvement driven by lower finance costs and a jump in 'other' income.

----------

DeepVerge PLC, down 7.4% at 31.49p, 12-month 16.6p-70p. The life science company conditionally raises GBP10 million via placing of 31.5 million shares and subscription for 1.8 million shares, at price of 30p each. Price represents discount of 12% to Friday's closing price. "This fundraising enables the Company, on three continents, to scale, to meet increased demand, while expanding revenues faster across the Group," says Chief Executive Gerry Brandon.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 Oct 2022 16:46

Scancell enrols and doses first patient in latest cancer trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.

Read more
28 Oct 2022 14:42

Scancell losses widen on expense of ongoing trials

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.

Read more
28 Oct 2022 11:57

IN BRIEF: Scancell narrows annual loss as vaccine candidates progress

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.

Read more
26 Oct 2022 14:30

IN BRIEF: Scancell executive chair and co-founder both to depart

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Read more
25 Oct 2022 14:34

Scancell inks licensing deal with Nasdaq-traded Genmab

(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.

Read more
25 Oct 2022 12:17

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster.

Read more
25 Oct 2022 10:44

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
25 Oct 2022 10:03

Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Read more
23 Sep 2022 13:31

Scancell presents new, positive data on possible cancer therapies

(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.

Read more
16 Aug 2022 17:51

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.

Read more
23 Jun 2022 21:28

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
23 Jun 2022 12:38

Scancell developing 'promising' new cancer treatment approach

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

Read more
15 Jun 2022 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.

Read more
15 Jun 2022 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval.

Read more
13 Jun 2022 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.